Researchers reveal TGF-β1 promotes scar tissue formation and restricts recovery CHINA, March 19, 2026 /EINPresswire.com/ — Fibrotic scarring is a major challenge in recovery post spinal cord injury ...

Cancer immunotherapy has transformed the treatment landscape for multiple malignancies; however, its clinical efficacy remains limited in many tumors due to ...

Mestag Therapeutics (“Mestag”), a biotech company harnessing fibroblast immunology to develop impactful treatments for patients with cancer and inflammatory diseases, today announced the closing of a ...

Hypertrophic scarring affects a large proportion of patients following burns, trauma, or surgery and arises from prolonged fibroblast hyperactivity and excessive extracellular matrix accumulation.

HOUSTON, March 12, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the ...

Breast cancer remains one of the most prevalent and life-threatening forms of cancer, impacting millions worldwide. This malignancy's heterogeneity and complexity have long posed significant ...

FibroBiologics is planning a prospective, multicenter, open-label clinical trial evaluating the safety, tolerability, and efficacy of CYWC628 in treating refractory diabetic foot ulcers with up to 12 ...

A study conducted by scientists from the Institut Pasteur has revealed that microbes protect the lungs from subsequently developing allergies and asthma. This long-term protection is "memorized" not ...

HOUSTON, March 02, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a ...

HOUSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a ...